Broad-Spectrum Micronutrient Supplementation in Patients Who
Develop Peripheral Neuropathy While Taking Stavudine or Didanosine
The results of the HIV Micronutrient Study were
presented at the 11th Conference on Retroviruses and Opportunistic Infections
held in San Francisco this February 2004. The results showed that the
patients who took a high-dose micronutrient formula (Dr.
Jon Kaiser's Immune Support Formula) experienced an average increase of 26% in their
CD4 counts during a 12 week period. The increase in CD4 count was statistically
significant in both the on-treatment and intent-to-treat analysis.
follows below is a summary of the study protocol.
This research was
funded in part by a generous grant from the Bristol-Myers Squibb Company.
It is the first study to look at broad spectrum micronutrient supplementation
as an adjunct to standard medical therapy for HIV-infected individuals.
Study Protocal Synopsis
Objective: To determine if broad-spectrum, micronutrient
supplementation is an effective, non-toxic treatment for medication-induced
peripheral neuropathy in HIV-infected patients.
Design: A randomized, double-blind, placebo-controlled,
clinical trial to study the use of high-dose broad-spectrum micronutrient
supplementation vs. placebo for the treatment of stavudine and/or didanosine-induced
peripheral neuropathy in patients with HIV infection.
Statistics: A 1:1 patient ratio, randomized to high-dose
vs. placebo arms, is to be analyzed.
Sample Size: A total of 60 patients are to be enrolled.
Study Population: Sixty HIV-infected patients who meet
the following criteria will be admitted to the study.
HIV infection. This diagnosis can be based on the medical history,
clinical signs and symptoms, or results of laboratory testing.
CD4 cells greater or equal to 100 cells/mm3.
Acute onset of lower extremity peripheral neuropathy, based on history
and physical exam, during the past twelve months.
Currently taking antiviral therapy with stavudine (D4T) and/or didanosine
(DDI), appropriately dosed based upon weight.
At least 18 years of age.
Women of child bearing potential must have a negative pregnancy test
within two weeks prior to randomization and agree to practice barrier
method birth control during the study period.
Willingness and ability to sign an informed consent statement and
to comply with the protocol.
Known allergy or intolerance to any nutrient supplements contained
in the treatment arm.
Active treatment for an acute opportunistic infection or malignancy,
except for non-systemic treatment of Kaposi's Sarcoma.
Symptoms of lower extremity peripheral neuropathy that have been present
for greater than twelve months.
CD4 cell count < 100 cells/mm3.
Vitamin B12 deficiency.
ALT greater than 10X normal range.
Serum creatinine greater or equal to 2.0 mg/dL.
Therapy with recombinant human growth hormone during the past week
and/or during the study period. Patients on prior therapy can participate
in the study providing they "wash out" during the period between
the screening and baseline visits.
Any pharmacologic treatment for peripheral neuropathy during the past
week ("wash out" for one week prior to baseline visit is required).
This includes both prescription and non-prescription- strength non-steroidal
anti-inflammatory drugs (NSAIDS), narcotic and non-narcotic analgesics,
tricyclic antidepressants, and anticonvulsant medications such as gabapentin
Acupuncture and/or massage therapy, specifically to treat peripheral
neuropathy symptoms, during the past four weeks.
Currently taking micronutrient or herbal supplements greater than
one multivitamin pill per day.
Study Intervention: Patients in both arms of the study
will consume one nutrient packet twice daily at the beginning of a meal.
Each micronutrient packet will include the following nutrients:
Each placebo nutrient packet will include an identical appearing packet
of placebo capsules.
Changes in pain intensity at 4, 8, and 12 weeks of treatment will
be assessed by the Neuropathy Inventory Linear Analog Scale (NILAS).
Changes in quality of life at 4, 8, and 12 weeks of treatment will
be assessed by the Linear Analog Scale Assessment (LASA) and the Medical
Outcomes HIV Health Survey (MOS-HIV).
Changes in the neurological examination at 4, 8, and 12 weeks of treatment
will be assessed by the Neurologic Examination Assessment Tool (NEAT).
The percentage of patients in each group able to continue their original
antiviral medications at 4, 8, and 12 weeks of treatment will be assessed.
The percentage of patients in each group able to avoid taking prescription
strength pain medications at 4, 8, and 12 weeks of treatment will be
Any changes in metabolic and immunologic measurements (including CD4
cells, HIV RNA, fasting plasma lactate, fasting lipid panel. fasting
insulin level, fasting glucose level, and liver function tests in each
group will be measured at 4, 8, and 12 weeks of treatment.
Safety Evaluations: Assessment of laboratory tests, vital
signs, as well as incidence and severity of adverse experiences will
be closely monitored by study personnel.
of the information listed on this site is meant to provide diagnosis
or treatment of a medical condition. If you are experiencing any symptoms
of ill health please contact a licensed medical doctor to diagnose,
treat, and address your medical needs.